BR112017014552A2 - ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado? - Google Patents
?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado?Info
- Publication number
- BR112017014552A2 BR112017014552A2 BR112017014552A BR112017014552A BR112017014552A2 BR 112017014552 A2 BR112017014552 A2 BR 112017014552A2 BR 112017014552 A BR112017014552 A BR 112017014552A BR 112017014552 A BR112017014552 A BR 112017014552A BR 112017014552 A2 BR112017014552 A2 BR 112017014552A2
- Authority
- BR
- Brazil
- Prior art keywords
- liver
- triglycerides
- decrease
- reduction
- producing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
análogos de calcitonina como um medicamento para produzir uma diminuição em triglicerídeos no fígado ou para reduzir o acúmulo de gordura no fígado de um indivíduo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1500263.7A GB201500263D0 (en) | 2015-01-08 | 2015-01-08 | Calcitonin analogues for treating diseases and disorders |
PCT/EP2016/050186 WO2016110525A1 (en) | 2015-01-08 | 2016-01-07 | Calcitonin analogues for treating diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017014552A2 true BR112017014552A2 (pt) | 2018-05-15 |
Family
ID=52597359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017014552A BR112017014552A2 (pt) | 2015-01-08 | 2016-01-07 | ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado? |
Country Status (17)
Country | Link |
---|---|
US (2) | US10350272B2 (pt) |
EP (1) | EP3247383A1 (pt) |
JP (1) | JP2018502854A (pt) |
KR (1) | KR20170120576A (pt) |
CN (1) | CN107206056A (pt) |
AU (1) | AU2016205994A1 (pt) |
BR (1) | BR112017014552A2 (pt) |
CA (1) | CA2969293A1 (pt) |
CL (1) | CL2017001773A1 (pt) |
CO (1) | CO2017007007A2 (pt) |
EA (1) | EA201791154A1 (pt) |
GB (1) | GB201500263D0 (pt) |
IL (1) | IL253026A0 (pt) |
MX (1) | MX2017008755A (pt) |
PE (1) | PE20171320A1 (pt) |
PH (1) | PH12017500988A1 (pt) |
WO (1) | WO2016110525A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201704429D0 (en) * | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
GB201707955D0 (en) * | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
GB201813677D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
WO2000033866A1 (en) | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Pharmaceutical compositions containing insulin |
AU4216700A (en) | 1999-04-05 | 2000-10-23 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
WO2004084870A1 (en) | 2003-03-28 | 2004-10-07 | Sigmoid Biotechnologies Limited | Solid oral dosage form containing seamless microcapsules |
GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
ES2436152T3 (es) | 2003-07-23 | 2013-12-27 | Novartis Ag | Uso de calcitonina en osteoartritis |
JP2007523050A (ja) | 2003-09-17 | 2007-08-16 | カイアズマ・リミテッド | 生物学的障壁を通した透過を容易にすることのできる組成物 |
JP2008506750A (ja) | 2004-07-22 | 2008-03-06 | ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー | チオール基を含む化合物の排出ポンプ抑制剤としての使用 |
US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
AU2006261909B2 (en) | 2005-06-24 | 2011-08-11 | Enteris Biopharma, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
EP2722054B1 (en) | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
PL1834635T3 (pl) | 2006-03-13 | 2012-01-31 | Advancell Advanced In Vitro Cell Tech S A | Stabilne układy nanokapsułek do podawania cząsteczek aktywnych |
ES2426445T3 (es) | 2006-04-07 | 2013-10-23 | Merrion Research Iii Limited | Forma de dosificación oral sólida que contiene un potenciador |
US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
BRPI1006943A2 (pt) * | 2009-01-22 | 2021-06-15 | Unigene Laboratories Inc. | peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes |
JP6170933B2 (ja) | 2011-11-02 | 2017-07-26 | キーバイオサイエンス・アクチエンゲゼルシャフト | ペプチドの使用 |
DK3068796T3 (en) * | 2013-11-14 | 2018-03-05 | Keybioscience Ag | CALCITONIN MIMETICS FOR THE TREATMENT OF DISEASES AND DISORDERS |
-
2015
- 2015-01-08 GB GBGB1500263.7A patent/GB201500263D0/en not_active Ceased
-
2016
- 2016-01-07 EP EP16700080.1A patent/EP3247383A1/en not_active Withdrawn
- 2016-01-07 CN CN201680005191.8A patent/CN107206056A/zh active Pending
- 2016-01-07 WO PCT/EP2016/050186 patent/WO2016110525A1/en active Application Filing
- 2016-01-07 KR KR1020177021071A patent/KR20170120576A/ko unknown
- 2016-01-07 JP JP2017535736A patent/JP2018502854A/ja active Pending
- 2016-01-07 CA CA2969293A patent/CA2969293A1/en not_active Abandoned
- 2016-01-07 US US15/542,191 patent/US10350272B2/en not_active Expired - Fee Related
- 2016-01-07 MX MX2017008755A patent/MX2017008755A/es unknown
- 2016-01-07 PE PE2017001166A patent/PE20171320A1/es unknown
- 2016-01-07 EA EA201791154A patent/EA201791154A1/ru unknown
- 2016-01-07 AU AU2016205994A patent/AU2016205994A1/en not_active Abandoned
- 2016-01-07 BR BR112017014552A patent/BR112017014552A2/pt not_active Application Discontinuation
-
2017
- 2017-05-29 PH PH12017500988A patent/PH12017500988A1/en unknown
- 2017-06-19 IL IL253026A patent/IL253026A0/en unknown
- 2017-07-04 CL CL2017001773A patent/CL2017001773A1/es unknown
- 2017-07-12 CO CONC2017/0007007A patent/CO2017007007A2/es unknown
-
2019
- 2019-07-15 US US16/511,815 patent/US20190328843A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2017008755A (es) | 2017-11-17 |
CA2969293A1 (en) | 2016-07-14 |
US20190328843A1 (en) | 2019-10-31 |
US20180264085A1 (en) | 2018-09-20 |
GB201500263D0 (en) | 2015-02-25 |
AU2016205994A1 (en) | 2017-06-15 |
KR20170120576A (ko) | 2017-10-31 |
CL2017001773A1 (es) | 2018-03-09 |
EP3247383A1 (en) | 2017-11-29 |
JP2018502854A (ja) | 2018-02-01 |
PE20171320A1 (es) | 2017-09-07 |
US10350272B2 (en) | 2019-07-16 |
WO2016110525A1 (en) | 2016-07-14 |
IL253026A0 (en) | 2017-08-31 |
CN107206056A (zh) | 2017-09-26 |
CO2017007007A2 (es) | 2018-01-31 |
PH12017500988A1 (en) | 2017-12-18 |
EA201791154A1 (ru) | 2017-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2018005709A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
GT201700072A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
ZA201608077B (en) | Combination, composition, and method of administering the combination or composition to animals | |
PL3349783T3 (pl) | Kompozycje i sposoby do leczenia chorób | |
PL3273942T3 (pl) | Plaster mikroigłowy do dostarczania składnika aktywnego do skóry | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
EA201691911A1 (ru) | Быстродействующие композиции инсулина | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
BR112017014552A2 (pt) | ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado? | |
IL251530A0 (en) | Use of cannabinoids in the treatment of skeletal muscle atrophy | |
BR112016028918A2 (pt) | tratamento de hipertrigliceridemia grave | |
BR112017007860A2 (pt) | método para tratar uma doença de gordura no fígado | |
IL265719A (en) | Fabp4 as a therapeutic target in skin diseases | |
PH12016502311A1 (en) | Omega-3 analogues | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
PH12016501326A1 (en) | (s)-3'-methyl-abscisic acid and esters thereof | |
CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. | |
EP3325096A4 (en) | SYSTEM AND METHOD FOR DELIVERING A LIGHT DETERMINED TO A FABRIC | |
PH12017501979A1 (en) | Pharmaceutical compound | |
DOP2015000290A (es) | Benzoxazoles sustituidos | |
AU360949S (en) | A component for an artificial honeycomb | |
UA112489C2 (uk) | Спосіб лікування вугрової хвороби шкіри обличчя та спини за індріксоном | |
PH12017500173A1 (en) | Post-harvest disease control agent and post-harvest disease control method | |
MX2016001802A (es) | Actividad cicatrizante de nanomateriales de hidroxiapatita con extracto de thl-80. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |